KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Assets: 2015-2024

Historic Non-Current Assets for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $1.9 billion.

  • BeOne Medicines' Non-Current Assets rose 2.55% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2.55%. This contributed to the annual value of $1.9 billion for FY2024, which is 20.44% up from last year.
  • BeOne Medicines' Non-Current Assets amounted to $1.9 billion in FY2024, which was up 20.44% from $1.6 billion recorded in FY2023.
  • Over the past 5 years, BeOne Medicines' Non-Current Assets peaked at $1.9 billion during FY2024, and registered a low of $640.1 million during FY2020.
  • For the 3-year period, BeOne Medicines' Non-Current Assets averaged around $1.6 billion, with its median value being $1.6 billion (2023).
  • Data for BeOne Medicines' Non-Current Assets shows a peak YoY soared of 45.60% (in 2020) over the last 5 years.
  • Over the past 5 years, BeOne Medicines' Non-Current Assets (Yearly) stood at $640.1 million in 2020, then surged by 43.99% to $921.6 million in 2021, then rose by 27.19% to $1.2 billion in 2022, then skyrocketed by 36.65% to $1.6 billion in 2023, then increased by 20.44% to $1.9 billion in 2024.